Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2 Study of Oral KIT Inhibitor THE-630 in Advanced GIST
2022-502087-21-00Phase 2Completed
- Sponsor
- Theseus Pharmaceuticals
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of THE-630 in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Theseus Pharmaceuticals. Primary endpoints: Safety profile, DLTs, MTD, and RP2D of THE-630 (Phase 1) and Confirmed overall response rate (ORR) per modified RECIST 1.1 (Phase 2). Started Jun 2023; status: completed.
02
Drugs
THE-630
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2022-502087-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502087-21-00.